ACH-Pioglitazone; ACT Pioglitazone; APO-Pioglitazone; JAMP-Pioglitazone; MINT-Pioglitazone; PMS-Pioglitazone [DSC]; PRO-Pioglitazone [DSC]; SANDOZ Pioglitazone [DSC] Warning This drug may cause or make heart failure worse. Tell your doctor if you have had heart failure. This drug may need to be avoided with some types of heart failure.
Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs. Pioglitazone should not be used in patients with heart failure or a history of heart failure. Pioglitazone: risk of bladder cancer (July 2024)
Pioglitazone is not recommended in patients with symptomatic heart failure. Initiation of pioglitazone in patients with established New York Heart Association
PharmaCare coverage for pioglitazone Pioglitazone is contraindicated for patients with New York Heart Association (NYHA) heart failure Classes
Pioglitazone tablets are not recommended in patients with symptomatic heart failure.( 5.1) Initiation of pioglitazone tablets in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated.
Pioglitazone hydrochloride is not recommended in patients with symptomatic heart failure and is contraindicated in patients with established NYHA Class III or IV heart failure. Serious side effects of pioglitazone
Pioglitazone Pioglitazone is contraindicated in patients with heart failure or a history of heart failure. Pioglitazone should be discontinued
Pioglitazone is not recommended in patients with symptomatic heart failure. Initiation of pioglitazone in patients with established New York Heart Association
Furthermore, discontinuation or dose reduction of pioglitazone must be considered. Pioglitazone is not recommended in patients with symptomatic heart failure. Initiation of pioglitazone in patients with established New York Heart Association (NYHA) class III or IV heart failure is contraindicated.
Comments